New cream treatment for actinic keratosis to prevent skin cancer
Official title: A Phase 2, randomized, double-blind, 4-arm, multicenter study to demonstrate the efficacy and safety of topical dosage formulations of a prescription drug product for actinic keratosis
Funded at Nanometics, LLC · NIH-10929505 · Data updated 2026-11-12
This study is testing a new cream that combines two ingredients to help treat actinic keratosis, which are spots on the skin that can lead to skin cancer, and it's for people looking for a safer and quicker way to get rid of these spots.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Nanometics, LLC NIH-funded |
| Lab location | 1 site (La Jolla, UNITED STATES) |
| Project start | September 14, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $1,000,000 |
| NIH project number | 5R44CA288166-02 |
| Project ID | NIH-10929505 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with actinic keratosis who are immunocompetent.
✕Less likely to help
Patients with compromised immune systems or those who do not have actinic keratosis may not benefit from this research.
What this research studies
This research investigates a new topical cream that combines calcipotriol and 5-fluorouracil to treat actinic keratosis, which are precursors to skin cancer. The study aims to demonstrate the cream's effectiveness and safety through a randomized, double-blind trial involving multiple centers. Patients will apply the cream, which works by activating the immune system to eliminate the lesions and reduce the risk of developing cutaneous squamous cell carcinoma. The goal is to provide a more effective treatment option with a shorter duration than existing therapies.
Why it matters
Potential benefit: If successful, this research could provide a more effective and quicker treatment for actinic keratosis, potentially reducing the risk of skin cancer.
How similar studies have gone: Previous studies have shown promising results with similar combinations of treatments for actinic keratosis, indicating potential for success.
Where this research is happening
-
Nanometics, LLC
La Jolla, United States Active
Researchers
- Principal investigator: Isaacman, Steven — Nanometics, LLC
- Study coordinator: Isaacman, Steven
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.